Nicotine Pouches Import to the Philippines

DTI regulation is the default pathway, but products carrying medical or health claims can trigger a separate Food and Drug Administration review process instead. Marketing and labelling should avoid therapeutic or cessation-related claims to stay within the DTI's consumer-product track rather than inadvertently triggering FDA jurisdiction.

An April 2026 draft order would require Philippine Standard (PS) certification for manufacturing facilities producing nicotine pouches sold in the country. This doesn't close the market, but it does raise the bar for which suppliers' facilities qualify — worth confirming Swepouch's or its manufacturing partners' certification status against this requirement before finalising a supply agreement for this market.

One unresolved point in our research: RA 11900 may have been drafted primarily with tobacco-derived nicotine in mind, and synthetic (non-tobacco-derived) nicotine — the type used in most modern nicotine pouches, including Swepouch's range — may fall outside the Act's scope entirely rather than being clearly covered by it. This is worth resolving with Philippine legal counsel before treating DTI registration as settled, rather than assuming the Act automatically applies.

• Resolve the scope question with Philippine legal counsel: does RA 11900 cover synthetic nicotine?
• Check the manufacturing facility. Ask for the certification status of the facility against the draft PS requirement before you sign a supply agreement.
• Confirm DTI registration requirements for the specific product.
• Keep claims off the pack and the website. Any therapeutic or cessation claim can push the product into FDA review.
• Start with a trial order while the draft order is finalised.

The draft order does not close the market, but it changes which suppliers qualify, so it belongs at the start of the conversation rather than the end. Ask the manufacturer for current certificates and for written confirmation of where the facility stands against the draft requirement. If the position is unclear, hold the first order until it is. Because the scope question also remains open, a small trial shipment under a clear agreement with your Philippine partner is a safer way to learn than a container.

In the Philippines, what you say about the product can decide which regulator you answer to. A nicotine pouch sold as a consumer product sits with the Department of Trade and Industry. A pouch described with medical or health claims can be pulled towards the Food and Drug Administration, whose review is a different and heavier process.

This boundary is easy to cross by accident. Phrases such as 'helps you quit', 'safer alternative' or any reference to treatment or cessation are the obvious risks, but the same can be true of packaging imagery, distributor sales material and social posts written by a retail partner. The sensible approach is to treat claims as a compliance item: write an approved list of statements, give it to every partner, and review any material you did not write yourself.

The scope question compounds this. If synthetic nicotine falls outside RA 11900, the product could be classified differently altogether, and claims would matter even more. Ask counsel to address both questions together, so that a single opinion covers what law applies and what you may say.

Practical sequence. Obtain the legal view on scope. Check the manufacturing facility against the draft certification. Settle the claims policy. Only then agree a trial order with a Philippine partner, with terms that allow you to stop if the final rules differ from the draft. Treat the first shipment as a way to learn how registration, customs and retail behave in practice, and keep volumes at a level where a regulatory change would be an inconvenience and not a loss.

Mistakes to avoid. Signing a supply agreement before the facility's status against the draft is known is the main one. Others are allowing a retailer to publish health claims for you, treating the DTI route as certain, and ordering a container when a smaller shipment would answer the same questions. Keep the contract flexible, the claims list short and the first order modest, and revisit the plan when the draft order is finalised.

Budget note. Legal advice on scope, a facility review and a modest trial order are the first three costs, in that order. Hold back on marketing spend until the legal answers are in, since a campaign built for a market that later changes its rules is the least recoverable cost of all.

This guide reflects publicly available information as of September 2026 and is not legal advice. Confirm current DTI registration requirements, the finalised scope of the 2026 PS-certification order, and — critically — whether synthetic nicotine falls within RA 11900's scope, with the Department of Trade and Industry or a licensed Philippine regulatory adviser before committing to product formulations.